Outcome of 282 patients treated with imatinib as first-line therapy at the Hammersmith Hospital. c-CCyRS (current CCyR survival) was defined as the probability of being alive and in CCyR at a given time point. The c-CCyRS is the analog of “current leukemia free-survival” and takes into account the fact that a patient who relapses on one drug may reachieve a CCyR on a second-line treatment. An event was defined as loss of a CCyR or CHR, progression to advanced phase, death, or imatinib discontinuation. (Figure is based on Marin et al.⁵ )